Prothrombin complex concentrate (PCC) products available for reversal of warfarin-associated coagulopathy
| Product (manufacturer) . | Factor levels . | |||
|---|---|---|---|---|
| II . | VII . | IX . | X . | |
| Available in the US | ||||
| PCCs, 3-factor (II,IX,X) | ||||
| Profilnine SD (Grifols)*,** | ≤ 150 | ≤ 35 | ≤ 100 | ≤ 100 |
| Bebulin VH (Baxter)* | 24-38 | < 5 | 24-38 | 24-38 |
| Available outside the US | ||||
| PCCs, 4-factor (II, VII, IX, X) | ||||
| Beriplex (CSL Behring) † | 20-48 | 10-25 | 20-31 | 22-60 |
| Octaplex (Octapharma) ‡ | 14-38 | 9-24 | 25 | 18-30 |
| Cofact (Sanguin), IU/mL§ | 14-35 | 7-20 | 25 | 14-35 |
| Prothromplex T (Baxter) ‖ | 30 | 25 | 30 | 30 |
| PPPSB-HT¶ | 20 | 20 | 20 | 20 |
| PCCs, 3-factor (II,IX,X) | ||||
| Prothromplex HT (Baxter)# | 30 | — | 30 | 130 |
| Product (manufacturer) . | Factor levels . | |||
|---|---|---|---|---|
| II . | VII . | IX . | X . | |
| Available in the US | ||||
| PCCs, 3-factor (II,IX,X) | ||||
| Profilnine SD (Grifols)*,** | ≤ 150 | ≤ 35 | ≤ 100 | ≤ 100 |
| Bebulin VH (Baxter)* | 24-38 | < 5 | 24-38 | 24-38 |
| Available outside the US | ||||
| PCCs, 4-factor (II, VII, IX, X) | ||||
| Beriplex (CSL Behring) † | 20-48 | 10-25 | 20-31 | 22-60 |
| Octaplex (Octapharma) ‡ | 14-38 | 9-24 | 25 | 18-30 |
| Cofact (Sanguin), IU/mL§ | 14-35 | 7-20 | 25 | 14-35 |
| Prothromplex T (Baxter) ‖ | 30 | 25 | 30 | 30 |
| PPPSB-HT¶ | 20 | 20 | 20 | 20 |
| PCCs, 3-factor (II,IX,X) | ||||
| Prothromplex HT (Baxter)# | 30 | — | 30 | 130 |
Product insert specifies: “Indicated for replacement of factor IX in patient with hemophilia B. Not indicated for treatment of factor VII deficiency.”
The values given for factor contents are the number of units present per 100 factor IX units in each vial. For all other values, IU/mL.
United Kingdom, European Union.
United Kingdom, Canada, European Union.
European Union.
Austria.
Japan
Australia.